Work

Theoretical Clinical Utility of Advanced Practice Provider Use of an Artificial Intelligence Radiomics-Based Tool for Pulmonary Nodule Evaluation and Management

Year: 2026

Type: article

Abstract: Background As integral members of pulmonary nodule (PN) programs, advanced practice providers (APPs) routinely evaluate PN cancer risk and make management recommendations. It is unknown whether an artificial intelligence (AI) tool impacts APP PN assessment and decision-making. Research Question What is the theoretical effect of APP use of a commercially available AI radiomics-based computer-aided diagnosis tool on PN diagnostic accuracy and management decision-making? Study Design and Methods In this retrospective, multireader, multicase study performed from May 2024 to June 2024, 6 APP readers (4 in pulmonology and 2 in thoracic surgery) independently evaluated 300 chest CT scan cases, each with an indeterminate PN 5 to 30 mm in maximal diameter (50% cancer prevalence). Using solely CT imaging data, APPs provided an estimate of cancer risk and management recommendation for each case without and then with AI tool assistance. The effect of the AI tool on readers' diagnostic performance and management decisions was assessed using descriptive statistics, area under the receiver operating characteristic curve, and reclassification plots and tables. Results With AI tool assistance, APP readers' average PN diagnostic accuracy increased by 9 percentage points (area under the receiver operating characteristic curve, 0.79 vs 0.88; P < .001). A higher proportion of malignant PNs were classified as high (> 65%) risk (63% vs 46%, P < .001) and recommended for a lung biopsy or surgical resection (72% vs 55%, P < .001) with AI tool assistance. Although benign PNs were more often classified as low (< 5%) risk (39% vs 34%, P < .001) with AI tool assistance, there was no statistically significant difference in the proportion recommended for an invasive procedure (18% vs 17%, P = .30). Interpretation Our results show that APP use of a commercially available AI radiomics-based tool for PN evaluation was associated with increased diagnostic accuracy and invasive diagnostic procedure recommendation for malignant PNs. Future prospective, randomized clinical trials are required to assess its use in routine clinical practice.

Source: CHEST Pulmonary

DOI: 10.1016/j.chpulm.2026.100242

Authors: Roger Y. Kim, Annika Rings, Lyndsey C. Pickup, Omar Ibrahim, Anil Vachani